21416-67-1
21416-67-1
Chemical Structure
Razoxane
Synonym(s): ICRF 159
- CAS No.: 21416-67-1
- Formula:C11H16N4O4
- Molecular Weight:268.27
IUPAC Name: 4,4'-(propane-1,2-diyl)bis(piperazine-2,6-dione)
InChIKey: BMKDZUISNHGIBY-UHFFFAOYSA-N
SMILES: CC(CN(CC(N1)=O)CC1=O)N(CC(N2)=O)CC2=O
Biological Activity: Razoxane (ICRF 159), a EDTA (HY-Y0682) derivative, is an orally active antiangiogenic topoisomerase II inhibitor. Razoxane has antineoplastic, antiangiogenic, and antimetastatic activities. Razoxanecan be used for the research of renal cell carcinoma (RCC), lung cancer and melanoma cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Razoxane | 99.78% | Razoxane (ICRF 159), a EDTA (HY-Y0682) derivative, is an orally active antiangiogenic topoisomerase II inhibitor. Razoxane has antineoplastic, antiangiogenic, and antimetastatic activities. Razoxanecan be used for the research of renal cell carcinoma (RCC), lung cancer and melanoma cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Razoxane (Standard) | ≥98% | Razoxane (Standard) is the analytical standard of Razoxane. This product is intended for research and analytical applications. Razoxane (ICRF 159) is an antiangiogenic topoisomerase II inhibitor, can be used for the research of renal cell carcinoma (RCC). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. J P Braybrooke, et al. A phase II study of Razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Clin Cancer Res.2000; 6(12):4697-704. [Content Brief]
- [2]. F Wingen, et al. Antimetastatic effects of Razoxane in a rat osteosarcoma model. Clin Exp Metastasis.Jan-Mar 1987; 5(1):9-16. [Content Brief]
Keywords
